Giulia Kennedy - Veracyte Chief Scientific Officer, Chief Medical Officer

VCYT Stock

USD 44.12 1.17 2.72%

Executive

Dr. Giulia C. Kennedy Ph.D., is the Chief Scientific Officer, Chief Medical Officer of VeraCyte, Inc. She has served as our Chief Scientific Officer since September 2008 and became our Chief Medical Officer in January 2018. Dr. Kennedy served as our Senior Vice President of Research and Development from April 2008 to September 2008. Prior to joining us, Dr. Kennedy was a Senior Director at Affymetrix, Inc., a microarray technology company, where she served from January 2000 to March 2008. Prior to joining Affymetrix, Dr. Kennedy served in scientific roles at Chiron Corporation and Millennium Pharmaceuticals, Inc., both of which are biotechnology companies since 2018.

Age	65
Tenure	6 years
Professional Marks	Ph.D
Address	6000 Shoreline Court, South San Francisco, CA, United States, 94080
Phone	650 243 6300
Web	https://www.veracyte.com

Kennedy holds a B.S. in Applied Science from Youngstown State University and a Ph.D. in Biochemistry from Case Western Reserve University School of Medicine and completed postdoctoral training in the Biochemistry Department and Hormone Research Institute at the University of California, San Francisco.

Veracyte Management Efficiency

The company has return on total asset (ROA) of 0.0107 % which means that it generated a profit of $0.0107 on every $100 spent on assets. This is way below average. Veracyte's management efficiency ratios could be used to measure how well Veracyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.24 in 2024. Return On Capital Employed is likely to drop to -0.09 in 2024. At this time, Veracyte's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 1.2 B in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 1.2 M in 2024.

Compare Veracyte to Peers

Predict price of Veracyte

Veracyte currently holds 12.63 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Veracyte has a current ratio of 4.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Veracyte's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives			EXECUTIVE Age
	Yingli Ma	Structure Therapeutics American	50
	Jennifer Viera	Enanta Pharmaceuticals	N/A
	Carl Morris	Solid Biosciences LLC	52
	Jennifer JD	Viridian Therapeutics	52
	Beth Mueller	AnaptysBio	N/A
	Anthony Casicano	Viridian Therapeutics	47
	Pete Spain	Kura Oncology	N/A
	Andrew Callos	Cytokinetics	55
	Mohammad Masjedizadeh	Protagonist Therapeutics	N/A
	Matt Yang	Cytokinetics	N/A
	Diane Weiser	Cytokinetics	N/A
	Steven Closter	Syndax Pharmaceuticals	N/A
	Bob Gatmaitan	Structure Therapeutics American	N/A
	Paul Barsanti	Ideaya Biosciences	N/A
	Robin Wagner	Keros Therapeutics	N/A
	Matthew Moore	Ventyx Biosciences	51
	JD Esq	Kura Oncology	53
	Dana MD	Crinetics Pharmaceuticals	68
	Abha Bommireddi	Protagonist Therapeutics	N/A
	Seth Harmon	Viridian Therapeutics	44
	Jim Flaherty	Rhythm Pharmaceuticals	N/A

The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis Prosigna Breast Cancer Assay for breast cancer diagnosis Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis and Immunoscore Colon Cancer test for colon cancer diagnosis. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Veracyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 761 people. Veracyte (VCYT) is traded on NASDAQ Exchange in USA. It is located in 6000 Shoreline Court, South San Francisco, CA, United States, 94080 and employs 815 people. Veracyte is listed under Biotechnology category by Fama And French industry classification.

Management Performance

	Return On Equity	-0.0083
	Return On Asset	0.0107

Veracyte Leadership Team

Elected by the shareholders, the Veracyte's board of directors comprises two types of representatives: Veracyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Veracyte. The board's role is to monitor Veracyte's management team and ensure that shareholders' interests are well served. Veracyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Veracyte's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Robert Brainin, Executive Officer
	John Leite, Chief Business
	Annie McGuire, Sr Counsel
	Tracy Morris, VP Communications
	Corinne Danan, Senior President
	Tina Nova, Director
	Bonnie Anderson, Co-Founder, CEO and President Director and Member of Non-Management Equity Award Committee
	Keith Gligorich, Senior Operations
	Rebecca Chambers, Executive CFO
	Jonathan Wygant, VP Officer
	Phillip MD, Chief Officer
	Beverly CPA, VP Controller
	Karen Possemato, Communications Marketing
	Giulia Kennedy, Chief Scientific Officer, Chief Medical Officer
	Steven French, Senior Officer
	Marc Stapley, CEO Director

Veracyte Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Veracyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-0.0083
	Return On Asset	0.0107
	Profit Margin	(0.02) %
	Operating Margin	0.11 %
	Current Valuation	3.07 B
	Shares Outstanding	77.5 M
	Shares Owned By Insiders	0.77 %
	Shares Owned By Institutions	99.23 %
	Number Of Shares Shorted	2.88 M
	Price To Earning	(10.61) X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Veracyte Stock Analysis

When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC